AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9506192
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (including long-acting dihydropyridines and nondihydropyridine agents)
Trial: 9506192
Drug: Short-acting agents
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting agents (e.g., nifedipine)
Trial: 8036828
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication at the time of vaccination
Trial: 8036828
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of medication at the time of vaccination
Trial: 23445320
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg·kg(‐1))
Trial: 23445320
Drug: Bupivacaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (2 mg·kg(‐1))
Trial: 20130841
Drug: pioglitazone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone (15-30 mg/day)
Trial: 20130841
Drug: metformin (500-750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin (500-750 mg/day)
Trial: 15995024
Drug: 1 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/kg IVIG over 2 days
Trial: 15995024
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg IVIG over 5 days
Trial: 15995024
Drug: 2 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/kg IVIG administered over 2 days
Trial: 15995024
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days treatment
Trial: 12850889
Drug: Test drink
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drink with antioxidants (450 ml/day for 4 weeks)
Trial: 12850889
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (450 ml/day for 4 weeks)
Trial: 9235072
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss and exercise intervention (12 weekly group sessions, 1 individual counseling session, 6 biweekly follow-up sessions)
Trial: 1662884
Drug: Temafloxacin 400
RxNorm normalized name: temafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 400 mg b.i.d. for 28 days
Trial: 31358540
Drug: Atezolizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 0.1 to 20 mg/kg or ≥10 mg/kg every 3 weeks
Trial: 17392697
Drug: Low‐fat (15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐fat (15% fat), high‐fiber (18 g/1000 kcal) diet supplemented with 40 g soy protein isolate (n=26)
Trial: 10804328
Drug: 20% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Intralipid (60 ml/h) and heparin (900 U/h) for 5.5 h
Trial: 20655660
Drug: Conventional conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional conservative orthopaedic treatment (COT)
Trial: 17717682
Drug: Alcohol in
RxNorm normalized name: WATER/BENZYL ALCOHOL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol in juice (1.4 g/l)
Trial: 15758565
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intravenous dexamethasone suppression test
Trial: 12036821
Drug: Calcium (1450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1450 mg/d) and vitamin D (10 microg (400 IU)/d)
Trial: 12036821
Drug: Calcium, vitamin
RxNorm normalized name: Vitamin B1 with Calcium, Vitamin B1 with Calcium oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium, vitamin D, and other nutrients (multinutrient supplement)
Trial: 10208191
Drug: Albuterol via
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 15 L/min
Trial: 10208191
Drug: Albuterol via
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 30 L/min
Trial: 10208191
Drug: Albuterol via
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol via Clickhaler (DPI) at 200 microg inhaled at 60 L/min
Trial: 10208191
Drug: Albuterol via
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol via pMDI inhaled at 30 L/min
Trial: 1844749
Drug: Diuretics alone
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics alone (23%)
Trial: 1844749
Drug: Beta blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blockers alone (32%)
Trial: 1844749
Drug: Diuretic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic and beta blocker (38%)
Trial: 1844749
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with vasodilators (9%)
Trial: 1844749
Drug: Other forms
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other forms of therapy (5%)
Trial: 31428433
Drug: Behaviour change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour change intervention (delivered over eight sessions as weekly one‐on‐one, face‐to‐face 40‐min consultations)
Trial: 31428433
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (pharmacological treatment and similar educational programmes)
Trial: 29871085
Drug: Reposition plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reposition plus drug treatment (Barbecue reposition maneuver + Alprostadil, Cinepazide, Betahistine)
Trial: 29871085
Drug: Reposition plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reposition plus drug treatment
Trial: 20854342
Drug: Foot massage
RxNorm normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot massage (20 min daily for 5 days)
Trial: 17983871
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension 0.5 mg once daily
Trial: 17983871
Drug: Montelukast 4
RxNorm normalized name: montelukast 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 4 or 5 mg once daily
Trial: 16027500
Drug: Hand-Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hand-Acupuncture therapy for 20 minutes
Trial: 6873004
Drug: Social alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Social alcohol intake (1-3 glasses of vodka mixed with orangeade, consumed twice a week for 16 weeks)
Trial: 24719139
Drug: ALN/D5600 (alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN/D5600 (alendronate 70 mg + 5600 IU vitamin D₃)
Trial: 24719139
Drug: ALN (alendronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALN (alendronate 70 mg without additional vitamin D)
Trial: 23767196
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 microgram stat) along with fluid and antibiotics
Trial: 23767196
Drug: Racecadotril (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril (1.5 mg/kg three times a day) along with fluid and antibiotics
Trial: 23767196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received only fluids and antibiotics
Trial: 19395036
Drug: Prior glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior glaucoma surgery with preoperative glaucoma medication use
Trial: 17848840
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with aspart or lispro insulin
Trial: 17848840
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) with once-daily glargine and human regular insulin at meals
Trial: 9862252
Drug: Irbesartan 25
RxNorm normalized name: Hydrochlorothiazide/Irbesartan 25 MG-300 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 25 mg capsules (two capsules after a 10 h fast)
Trial: 7650233
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine alone (group 1)
Trial: 7650233
Drug: Td vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Td vaccine plus 500 IU of TIG (group 2)
Trial: 805518
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of pteroylglutamic acid
Trial: 22672107
Drug: Cilostazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (100 mg daily)
Trial: 22672107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Aspirin 100 mg or Clopidogrel 50 mg‐75 mg daily)
Trial: 21663422
Drug: Lithium 300
RxNorm normalized name: lithium 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium 300 mg twice daily (Arm I)
Trial: 21663422
Drug: Lithium 300
RxNorm normalized name: lithium 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium 300 mg thrice daily (Arms II and III)
Trial: 21663422
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (all arms)
Trial: 16965240
Drug: Combination low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low fat, high FV
Trial: 11151749
Drug: Ciprofloxacin 250
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 250 mg twice daily for 7 days
Trial: 3704451
Drug: Methylphenidate (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10, 30, or 60 mg/day)
Trial: 3704451
Drug: Pemoline (18.75,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemoline (18.75, 56.25, or 112.5 mg/day)
Trial: 3704451
Drug: Protriptyline (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protriptyline (10, 30, or 60 mg/day)
Trial: 25005346
Drug: Fixed Tc-99m-tetrofosmin
RxNorm normalized name: Tc-99m tetrofosmin
DrugBank: Technetium Tc-99m tetrofosmin (DB09160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Tc-99m-tetrofosmin tracer dose
Trial: 25005346
Drug: Body weight-dependent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body weight-dependent tracer dose and scan time
Trial: 21495052
Drug: Behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family therapy (BFT) plus fluoxetine
Trial: 21495052
Drug: Behavioral family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral family therapy (BFT) plus placebo
Trial: 21495052
Drug: Systems family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systems family therapy (SFT) plus fluoxetine
Trial: 21495052
Drug: Systems family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systems family therapy (SFT) plus placebo
Trial: 18978102
Drug: Mifepristone 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 5 mg
Trial: 8984147
Drug: Troxerutin 3,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin 3,500 mg
Trial: 8984147
Drug: Troxerutin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troxerutin 1,000 mg twice daily
Trial: 1837496
Drug: Acute verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute verapamil administration (160 mg)
Trial: 1837496
Drug: Chronic verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic verapamil treatment (240 mg/day for 12 months)
Trial: 6122652
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg flunitrazepam orally the night before operation and 1 mg on the morning of operation (group 1)
Trial: 6122652
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pentobarbital orally the night before operation, followed by intramuscular scopolamine (0.006 mg/kg) + morphine (0.02 mg/kg) on the morning of operation (group 2)
Trial: 28844361
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive therapy
Trial: 21371164
Drug: Formulated Collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated Collagen Gel (FCG)
Trial: 19835120
Drug: Nitramisole cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitramisole cream (NC)
Trial: 17907004
Drug: Micronized estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized estradiol 2 mg/day
Trial: 17907004
Drug: Micronized estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micronized estradiol 2 mg/day plus norethisterone acetate 1 mg/day
Trial: 12040360
Drug: Terbogrel (thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbogrel (thromboxane synthetase inhibitor and receptor antagonist) for 12 weeks
Trial: 9873846
Drug: Asserachrom VIII:CAg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asserachrom VIII:CAg ELISA using monoclonal antibodies (MoAbs 833 and D4H1)
Trial: 8848535
Drug: Lorazepam (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1.2 mg)
Trial: 688767
Drug: Topical clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clotrimazole (Lotrimin)
Trial: 688767
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ultramicrosize griseofulvin and topical clotrimazole
Trial: 25994853
Drug: Erlotinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib administered 2 hours after a meal
Trial: 25994853
Drug: Erlotinib administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib administered in complete fasting
Trial: 24152604
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg empagliflozin under fasted conditions
Trial: 24152604
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg empagliflozin after a high‐fat, high‐calorie breakfast
Trial: 24152604
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg empagliflozin under fasted conditions
Trial: 14969628
Drug: Carbon-coated stents
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbon-coated stents (CC)
Trial: 11355930
Drug: Granulocyte-macrophage (GM)-CSF
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage (GM)-CSF or Granulocyte (G)-CSF
Trial: 11355930
Drug: Cytokines (e.g.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokines (e.g. pegylated recombinant human megakaryocytic growth and development factor + G- or GM-CSF)
Trial: 11355930
Drug: Therapies targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies targeting cytokine receptors on AML blasts
Trial: 9153103
Drug: EPO administration
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO administration (120 U/kg per week for 5 to 8 months)
Trial: 26222158
Drug: Channa striatus
RxNorm normalized name: Labrus striatus flesh
DrugBank: Black sea bass (DB15547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Channa striatus extract (500 mg daily for six weeks)
Trial: 26222158
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg maltodextrin daily for six weeks)
Trial: 21967936
Drug: Rapid maxillary
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid maxillary expansion and facemask therapy
Trial: 16646643
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene protocol managed by a dental hygienist
Trial: 14608343
Drug: no decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no decontamination therapy
Trial: 8922008
Drug: Intermittent nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulized (IN) albuterol (0.15 mg/kg/dose every 30 min)
Trial: 8922008
Drug: Continuous nebulized
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulized (CN) albuterol (0.3 mg/kg/hr)
Trial: 8922008
Drug: Continuous nebulized
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulized (CN) albuterol
Trial: 8922008
Drug: Intermittent nebulized
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulized (IN) albuterol
Trial: 3919415
Drug: Second-line anti-rheumatic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line anti-rheumatic drugs (e.g., gold) continuously for 12 months
Trial: 27485930
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Group Therapy for elderly with Type 2 diabetes and minor depression
Trial: 24810476
Drug: Taikong Yangxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taikong Yangxin Prescription (TYP)
Trial: 19955769
Drug: Cold-blood cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-blood cardioplegia enriched with N-acetylcysteine (NAC) (50 mg/kg)
Trial: 18703004
Drug: Ustekinumab 27
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 27 mg
Trial: 18703004
Drug: Ustekinumab 90
RxNorm normalized name: ustekinumab 90 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 90 mg q8w
Trial: 18703004
Drug: Ustekinumab 180
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab 180 mg
Trial: 8832600
Drug: Three 20-micrograms
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 20-micrograms doses at 0, 1, and 2 months (group II)
Trial: 8832600
Drug: Three 20-micrograms
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 20-micrograms doses at 0, 1, and 6 months (group III)
Trial: 8832600
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose schedule of three 10-micrograms doses at 0, 1, and 2 months (group I)
Trial: 1596903
Drug: Control patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control patients (not treated with the autologous colon tumor vaccine)
Trial: 25292404
Drug: Fructo-oligosaccharides (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo-oligosaccharides (20 g daily for 30 days)
Trial: 24874483
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg day(-1) + Celecoxib 800 mg day(-1)
Trial: 24874483
Drug: Exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane 25 mg day(-1)
Trial: 11215733
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg [13C]urea + Ensure
Trial: 11215733
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg [13C]urea + citric acid
Trial: 9124988
Drug: Piperacillin/tazobactam (P/T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (P/T) administered as 30‐minute intravenous infusions 4 or 3 times a day for 3 to 13 days
Trial: 3088662
Drug: Oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral scopolamine 0.15 mg
Trial: 3088662
Drug: Oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral scopolamine 0.3 mg
Trial: 3088662
Drug: Oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral scopolamine 0.6 mg
Trial: 3088662
Drug: Oral scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral scopolamine 1.2 mg
Trial: 3088662
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine and higher oral dose conditions
Trial: 3088662
Drug: Transdermal scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal scopolamine patch
Trial: 31366300
Drug: Phenylephrine dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine dose
Trial: 29589820
Drug: UC+TxtM (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC+TxtM (usual care plus twice-daily diabetes self-management text messages)